CEOS see Quick ROI on Digital Transformation and AI Investments

Sep 07, 2018
By Pharmaceutical Executive Editors

KPMG—a business solutions, audit, tax, and advisory professional services firm—released its 2018 CEO Outlook. The report found that CEOs at large life sciences companies anticipate quickly recovering investments in digital transformation and artificial intelligence (AI), while those in the U.S. expect, or have accomplished, quicker returns than their global peers.

Among the U.S. CEOs surveyed this year, 25% said they have already achieved significant returns from AI investments and also digital transformation programs that have reshaped business functions such as product development, finance, IT, human resources, regulatory compliance, and marketing. Only 9% of global life sciences CEOs said they’ve already achieved a significant return on investment in AI and digital transformation programs.

Another 33% of CEOs surveyed—globally and in the U.S.—expect their investments in digital transformation to pay off within 12 months, the survey found.

 

native1_300x100
lorem ipsum